Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090927159> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2090927159 endingPage "18" @default.
- W2090927159 startingPage "7" @default.
- W2090927159 abstract "Objectives: To determine whether tizanidine [Zanaflex™] would demonstrate clinical efficacy in patients with fibromyalgia [FMS] in an open label study over 14 weeks.Methods: Forty-six consecutive patients with a diagnosis of FMS were treated with tizanidine. Prior to and at seven and 14 weeks each patient was evaluated by the total number of tender points [TePs], the Fibromyalgia Impact Questionnaire [FIQ] score, and visual analog scales [VAS] for pain, sleep, fatigue, and patient global assessment. Patients were also analyzed based on employment status with an employed/retired [E/R] group and a disabled/applying [D/A] group.Results: Of the 46 initial patients, 30 patients completed seven weeks and showed a significant decrease in TePs [P < 0.001] and a significant improvement in VAS pain [P < 0.01], VAS sleep [P < 0.05], VAS fatigue [P < 0.02], and FIQ scores [P < 0.01]. By week 14, improvement was limited to TePs [P < 0.01] and VAS fatigue [P < 0.01]. The severity of FMS at the beginning of the study was not significantly different between the E/R group and the D/A group. There was significant improvement in the E/R group in TePs, VAS pain, fatigue, and FIQ scores at both weeks seven and 14. In contrast, this was not seen in the D/A group.Conclusion: Tizanidine is a useful medication in the treatment of FMS as judged by this open label uncontrolled study. The response as judged by TePs, VAS pain and fatigue, and FIQ scores was significantly better in the E/R group as opposed to the D/A group although there was no significant demographic difference between the groups. Employment status appears to be an important variable in the response achieved in this clinical trial." @default.
- W2090927159 created "2016-06-24" @default.
- W2090927159 creator A5061093478 @default.
- W2090927159 date "2002-01-01" @default.
- W2090927159 modified "2023-09-25" @default.
- W2090927159 title "An Open Label Dose Finding Trial of Tizanidine [Zanaflex™] for Treatment of Fibromyalgia" @default.
- W2090927159 cites W1969561310 @default.
- W2090927159 cites W1984085801 @default.
- W2090927159 cites W1988578107 @default.
- W2090927159 cites W2030247666 @default.
- W2090927159 cites W2036910356 @default.
- W2090927159 cites W2041481324 @default.
- W2090927159 cites W2046644701 @default.
- W2090927159 cites W2050155781 @default.
- W2090927159 cites W2059150038 @default.
- W2090927159 cites W2108628123 @default.
- W2090927159 cites W2151099642 @default.
- W2090927159 cites W2253364553 @default.
- W2090927159 cites W2346744058 @default.
- W2090927159 cites W72436669 @default.
- W2090927159 cites W753735195 @default.
- W2090927159 doi "https://doi.org/10.1300/j094v10n04_02" @default.
- W2090927159 hasPublicationYear "2002" @default.
- W2090927159 type Work @default.
- W2090927159 sameAs 2090927159 @default.
- W2090927159 citedByCount "6" @default.
- W2090927159 countsByYear W20909271592022 @default.
- W2090927159 crossrefType "journal-article" @default.
- W2090927159 hasAuthorship W2090927159A5061093478 @default.
- W2090927159 hasConcept C126322002 @default.
- W2090927159 hasConcept C14184104 @default.
- W2090927159 hasConcept C168563851 @default.
- W2090927159 hasConcept C1862650 @default.
- W2090927159 hasConcept C2777831278 @default.
- W2090927159 hasConcept C2779012798 @default.
- W2090927159 hasConcept C2779761043 @default.
- W2090927159 hasConcept C3019800554 @default.
- W2090927159 hasConcept C42219234 @default.
- W2090927159 hasConcept C71924100 @default.
- W2090927159 hasConceptScore W2090927159C126322002 @default.
- W2090927159 hasConceptScore W2090927159C14184104 @default.
- W2090927159 hasConceptScore W2090927159C168563851 @default.
- W2090927159 hasConceptScore W2090927159C1862650 @default.
- W2090927159 hasConceptScore W2090927159C2777831278 @default.
- W2090927159 hasConceptScore W2090927159C2779012798 @default.
- W2090927159 hasConceptScore W2090927159C2779761043 @default.
- W2090927159 hasConceptScore W2090927159C3019800554 @default.
- W2090927159 hasConceptScore W2090927159C42219234 @default.
- W2090927159 hasConceptScore W2090927159C71924100 @default.
- W2090927159 hasIssue "4" @default.
- W2090927159 hasLocation W20909271591 @default.
- W2090927159 hasOpenAccess W2090927159 @default.
- W2090927159 hasPrimaryLocation W20909271591 @default.
- W2090927159 hasRelatedWork W145485953 @default.
- W2090927159 hasRelatedWork W2019470479 @default.
- W2090927159 hasRelatedWork W2090927159 @default.
- W2090927159 hasRelatedWork W2162235459 @default.
- W2090927159 hasRelatedWork W2909252410 @default.
- W2090927159 hasRelatedWork W2952267126 @default.
- W2090927159 hasRelatedWork W2955267374 @default.
- W2090927159 hasRelatedWork W3176353805 @default.
- W2090927159 hasRelatedWork W4200329721 @default.
- W2090927159 hasRelatedWork W4200554107 @default.
- W2090927159 hasVolume "10" @default.
- W2090927159 isParatext "false" @default.
- W2090927159 isRetracted "false" @default.
- W2090927159 magId "2090927159" @default.
- W2090927159 workType "article" @default.